A Montana therapeutic drug developer and California biotech company have agreed to collaborate on novel approaches for treating disorders of the central nervous system.
Last year, Kalispell, Mont.-based Expesicor and Novoron Bioscience of San Diego began working together on a compound for the treatment of neurodegenerative disorders like Alzheimer's disease. They've since co-developed a compound that is in preclinical testing.
Expesicor has considerable experience in drug development for neurological disorders and has developed proprietary therapeutics, imaging probes and drug-screening tools for epilepsy, neurodegenerative disorders, depression, autism and other brain disorders.
Novoron has implemented a novel approach to restoring the regenerative capacity of the brain and spinal cord, and is advancing its channel of biologic therapeutics for the treatment of multiple sclerosis and spinal cord injury.